

PrEP for Women

Together, we can change the course of the HIV epidemic...one woman at a time.

#onewomanatatime

#thewellproject



What Is PrEP?

PrEP stands for

Pre-

Exposure

Prophylaxis:



Prophylaxis: Taking medicine **before** being exposed to something, to prevent yourself from getting a disease or condition



What Is PrEP?

We use **several kinds of medicine** this way:

- Taking anti-malaria medication when we travel to areas where we might be bitten by mosquitoes that carry malaria
 - When medicine is in a person's body before getting a mosquito bite,
 (s)he is much less likely to get malaria when bitten
- For women, taking birth control pills (contraceptives)
 - Chances of pregnancy greatly reduced when contraceptives are already in a woman's body when exposed to semen during sex
- PrEP in connection to HIV and women: HIV-negative individuals taking HIV drugs to reduce their risk of becoming HIV positive if exposed to the virus



How Does PrEP Prevent the Spread of HIV?

- CD4 cells infected with HIV become little factories that make thousands of new viruses each day
 - HIV drugs work by blocking HIV from making copies of itself
- If an HIV-negative woman already has HIV drugs in her bloodstream when she is exposed to HIV during sex without condoms:
 - Medicine might be able to keep the HIV from making enough copies of itself to "take hold"
 - May prevent her from becoming HIV positive



Approval for Daily Oral PrEP

July 2012: U.S. Food and Drug Administration (FDA) approved daily Truvada (tenofovir disoproxil fumarate + emtricitabine, or TDF/FTC) as PrEP for sexually active adults at risk of HIV

- Truvada often used as part of combination HIV drug treatment
- First time FDA has approved any drugs for prevention of HIV
 June 2016: World Health Organization (WHO) releases updated guidelines recommending daily oral PrEP be offered as additional prevention method for all people at substantial risk of HIV
- WHO approves either Viread (tenofovir/TDF) or Truvada for daily oral PrEP



Has PrEP Been Shown to Be Effective?

Efficacy shown

- iPrex, TDF2, Partners studies tested Truvada
 - Conducted among men who MSM and transwomen in U.S. and Latin America
 - Among heterosexual women, men in several African countries
 - Effectiveness varied from 44 73% additional protection against
 HIV
- Study in Bangkok tested tenofovir (Viread) as PrEP
 - Among >2,400 HIV-negative women and men who inject drugs
 - Reduced risk of getting HIV by almost half



Has PrEP Been Shown to Be Effective?

Efficacy shown: Partners Demonstration Project

- Nearly eliminated HIV transmission among >1,000 serodifferent heterosexual couples in Kenya, Uganda
- Tested PrEP + treatment as prevention, with PrEP as a "bridge"
 - HIV-negative partner took PrEP while partner living with HIV took first 6 months of ARVs
- Completed in December 2016; only 1 new infection noted in primary results through July 2014
 - 96% reduction in new HIV cases
- Applies to all new infections, including those from someone other than one's regular sexual partner



Has PrEP Been Shown to Be Effective?

Other studies have found PrEP not to be effective

- FemPrEP study
 - Tested Truvada in Kenyan, Tanzanian, South African women at high risk for HIV
 - Stopped early did not seem to help in preventing HIV transmission
- VOICE study
 - >5,000 women in South Africa, Zimbabwe, Uganda
 - Tested:
 - Oral daily tenofovir
 - Oral daily Truvada
 - 1% tenofovir vaginal gel
 - Found all three methods ineffective in preventing HIV transmission



Why Are Some Research Findings Unclear?

For HIV prevention tools (condoms, PrEP, etc.) to work, they *have to be used – correctly and consistently*

- Adherence was the key factor for success in PrEP studies
- FemPrEP and VOICE studies:
 - Low levels of adherence; fewer than 1 in 3 women took drug regularly
 - Many women in FemPrEP study did not consider themselves at risk for HIV
- Studies that showed benefit had much higher rates of adherence
 - People who took PrEP as prescribed were much less likely to become HIV positive
 - CDC says that in people at high risk for HIV who take PrEP consistently, risk can be reduced by 92%



Why Are the Research Findings Unclear?

- Reasons why people especially women had low levels of adherence to oral PrEP is not yet fully understood
- Very important to do more research looking at what issues might affect women's interest in or ability to take a drug for HIV prevention
- Also important for women to know about and take part in future research that will look at unanswered questions about PrEP



CDC Guidelines for PrEP Use

May 2014: CDC released updated guidelines for PrEP use in U.S.

- Recommend PrEP with daily, oral Truvada be considered for HIVnegative people who are at substantial risk for HIV, including people who:
 - Are in a sexual relationship with a partner living with HIV
 - Don't regularly use condoms/don't know HIV status of sexual partner(s)
 - Have high number of sexual partners
 - Are engaged in commercial sex work
 - Have had recent bacterial sexually transmitted disease
 - Use injections drugs and
 - Share drug equipment, or
 - Were recently in a drug treatment program



CDC Guidelines for PrEP Use

- Some reasons PrEP is <u>not</u> recommended; having
 - Unknown HIV status (it's important that only people who test negative for HIV take PrEP)
 - Signs or symptoms of acute HIV infection
 - Decreased kidney function
 - Unknown hepatitis B status and/or vaccination status
- Guidelines suggest providers consider PrEP for people in areas or personal networks where HIV is more common, offer tools to help providers identify these areas



CDC/WHO PrEP Guidelines

- To provide high-level protection, PrEP needs to be
 - Taken for 7 days before anal sex; up to 20 days before vaginal sex
 - Used with other HIV prevention strategies (condoms, safer injecting practices)
 - Not intended to be used alone
 - Not proven 100 percent effective
- Everyone prescribed Truvada as PrEP have negative HIV test
 - CDC recommends people on PrEP be tested every 3 months to make sure they remain HIV-negative
- WHO recommends tenofovir or Truvada be offered to all people at substantial risk of HIV



PrEP and Pregnancy

- CDC: HIV-negative women who are pregnant/trying to become pregnant should talk with providers about risks and benefits of PrEP
- U.S. Public Health Service: providers should discuss PrEP as option to protect HIV-negative partners in serodifferent couples interested in getting pregnant
- Both Viread and Truvada appear safe in early pregnancy when used as PrEP
 - Partners PrEP study showed no negative effect on babies conceived when mother taking PrEP
 - Women living with HIV have been taking these drugs safely during pregnancy for many years



The PrEP Debate

- You may have heard debate about PrEP while many believe it's a good addition to the prevention toolbox, others disagree
- Following are several of the arguments against PrEP and response to those arguments

Concerns about PrEP

- HIV-negative people may not adhere; PrEP won't be effective
- PrEP will be used in place of condoms or other safer sex measures

Advatages of PrEP

- PrEP can be taken without agreement or knowledge of one's sex partner
- Research has not shown that using PrEP has reduced use of condoms/other safer sex methods

www.thewellproject.org



The PrEP Debate

Concerns about PrEP

- Possible side effects
 - Most common: nausea and vomiting
- Occasional serious effects of Truvada (bone, kidney or liver problems, lactic acidosis, lipodystrophy, etc)

Advantages of PrEP

- Most effects occur among people taking new HIV drug; often go away quickly
- No serious side effects found during PrEP studies
 - Small decrease in bone mineral density in men and transgender women in recent PrEP study

Many national and international guidelines recommend PrEP as a prevention tool, though others are still seeking more information and research.



What Does PrEP Mean for Women?

We now have evidence that PrEP works in preventing HIV if taken as prescribed, but *much more work needs to be* done before PrEP can be widely used and accepted

- Improving health care systems so people can access and afford PrEP
- Making HIV testing more widely available
 - Only people who know they are HIV-negative can use PrEP safely
 - If HIV-negative people taking PrEP become HIV positive, don't know it, and continue taking Truvada, they are much more likely to develop drug-resistant HIV



What Does PrEP Mean for Women?

PrEP is a promising tool that women can use to *prevent*HIV without their partners' cooperation

- Many questions remain:
 - How will taking PrEP affect pregnancy and breastfeeding?
 - How will women get tested, especially if their partners won't?
 - Will they be able to get PrEP if they don't know their partners' status?
 - Will men refuse condoms if they know their partner is on PrEP?
 - Will women be able to keep PrEP drugs given to them?
 - Some women worry drugs given to them might be taken away, given to another family member who "needs them more"
- These and other questions are currently being explored in research and advocacy efforts in the U.S. and worldwide



Considering Taking Truvada as PrEP?

Questions to discuss with your provider:

- How often—and for how long—do I need to take PrEP?
- What happens if I miss a dose/several doses?
- What are Truvada's likely side effects and how will I manage them?
- How often will I need to be tested for HIV?
- How much will the drug cost me?
 - Will it be covered by my insurance?
 - Will HIV tests also be covered by my insurance?



Considering Taking Truvada as PrEP?

More questions to discuss with your provider:

- Do any of my current medical conditions make Truvada a less-good choice?
- Do any of my other prescription medications, OTC drugs, street drugs, herbs, vitamins, supplements have interactions with Truvada?
- What should I do if I become pregnant while on PrEP?
- Pros and cons of PrEP compared to other safer sex techniques?



New Developments in the PrEP Arena

Tenofovir alafenamide (TAF):

- Can be given at lower doses than TDF (the form in Viread and Truvada)
- Less bone loss; less reduction in kidney function
 - FDA approved TAF + emtricitabine (Descovy) for HIV treatment in April 2016; study of TAF as PrEP ongoing



New Developments in the PrEP Arena

Long-acting injectable PrEP:

- Cabotegravir (integrase inhibitor)
- Shots found safe and tolerable in ÉCLAIR study
- May reduce burden of adherence to daily pill

Maraviroc (Selzentry):

 Safe and well tolerated as PrEP in small study of US women; fewer bone and kidney effects



Learn More!

- To learn more, and for links to fact sheet featuring more details, please read the full fact sheet:
 - PrEP for Women
- For more fact sheets and to connect to our community of women living with HIV, visit:
 - www.thewellproject.org
 - www.facebook.com/thewellproject
 - www.twitter.com/thewellproject